Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Callari

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Nature Communications|February 21, 2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancerJuan Blanco-Heredia, Carla Anjos Souza, Juan L Trincado, et al.
Cancer Research|November 8, 2024
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Yaniv Eyal-Lubling, Daniel Guerrero-Romero, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Cell|September 20, 2016
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsAlejandra Bruna, Oscar M Rueda, Wendy Greenwood, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Nature Communications|February 21, 2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancerJuan Blanco-Heredia, Carla Anjos Souza, Juan L Trincado, et al.
Cancer Research|November 8, 2024
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Yaniv Eyal-Lubling, Daniel Guerrero-Romero, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Cell|September 20, 2016
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsAlejandra Bruna, Oscar M Rueda, Wendy Greenwood, et al.
Pageof 7